Will gained his PhD in 1991, in Immunology and Virology sponsored by Unilever (UniPath), before holding a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC). He went on to Procter & Gamble Healthcare, where he was responsible for clinical development in a number of therapeutic areas, including respiratory and GI. He led and delivered programmes throughout Europe, the Americas, South Africa and China.
Additional to CellCentric, Will advises and represents other Morningside biotech interests (including VaxEquity, Cyted, F2G). In 2011 he was appointed by the Science Minister to the Council of the BBSRC, the UK’s leading funder of bioscience research. He subsequently took over as Chair of the John Innes Centre, the world-leading research institute focused on plant science and microbiology, stepping down in April 2021. In 2012 Will was elected to the Board of the BioIndustry Association, and subsequently was part of the Executive Committee. In addition to his doctorate, Will holds a Masters degree in Clinical Research as well as an MBA from London Business School.